Jolanda Howe Sells 1,840 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 1,840 shares of the business’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $105.29, for a total transaction of $193,733.60. Following the transaction, the senior vice president owned 1,274 shares in the company, valued at approximately $134,139.46. The trade was a 59.09% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jolanda Howe also recently made the following trade(s):

• On Wednesday, July 1st, Jolanda Howe sold 2,721 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $120.00, for a total transaction of $326,520.00.
• On Wednesday, June 17th, Jolanda Howe sold 2,594 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $101.95, for a total transaction of $264,458.30.

Mirum Pharmaceuticals Stock Performance

Shares of MIRM opened at $94.11 on Friday. The company has a market cap of $5.74 billion, a PE ratio of -6.47 and a beta of 0.52. The firm has a 50-day moving average of $110.35 and a 200-day moving average of $101.79. Mirum Pharmaceuticals, Inc. has a one year low of $54.74 and a one year high of $130.00. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.09 and a quick ratio of 1.99.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its earnings results on Wednesday, August 5th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.32). Mirum Pharmaceuticals had a negative net margin of 139.18% and a negative return on equity of 26.88%. The firm had revenue of $176.24 million during the quarter, compared to analyst estimates of $166.33 million. During the same quarter last year, the business posted ($0.12) earnings per share. The company’s revenue for the quarter was up 37.9% on a year-over-year basis. As a group, equities analysts forecast that Mirum Pharmaceuticals, Inc. will post -2.01 earnings per share for the current year.

Key Headlines Impacting Mirum Pharmaceuticals

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Mirum reported second-quarter revenue of approximately $176.2 million, ahead of the $166.3 million analyst consensus and up 37.9% year over year. Growth from Livmarli and other bile-acid medicines supported the performance. Mirum Q2 earnings and 2026 outlook
• Positive Sentiment: The company raised its 2026 revenue guidance to $680 million-$700 million, above the roughly $675.1 million consensus estimate, reinforcing expectations for continued product-driven growth.
• Positive Sentiment: Despite reducing their targets, TD Cowen and HC Wainwright maintained “buy” ratings at $140, while Citizens JMP kept a “market outperform” rating with a $137 target. These targets imply substantial potential upside from recent trading levels. Analyst price target updates
• Neutral Sentiment: Analysts continue to view Mirum favorably overall, but the target reductions—from as high as $185 previously—indicate that near-term risks and valuation assumptions have become more cautious.
• Negative Sentiment: Citizens warned that the FDA made an “unexpected” request for an additional Phase 3 study, clouding Mirum’s near-term outlook. The request raises potential development costs and could delay regulatory progress, which was the primary catalyst behind the selloff. Citizens FDA assessment
• Negative Sentiment: Second-quarter earnings missed expectations: Mirum reported a larger-than-expected per-share loss, while the loss widened from the prior-year period. The company remains unprofitable, increasing investor sensitivity to clinical spending and regulatory delays. Mirum quarterly earnings report
• Negative Sentiment: Senior Vice President Jolanda Howe sold 1,840 shares worth approximately $193,734 under a pre-arranged Rule 10b5-1 plan. The scheduled nature limits its significance, but the transaction reduced her direct holdings by about 59%. Mirum insider sale

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on MIRM shares. Morgan Stanley set a $137.00 price objective on Mirum Pharmaceuticals in a research report on Thursday. Wall Street Zen cut Mirum Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Citizens Jmp dropped their price target on Mirum Pharmaceuticals from $146.00 to $137.00 and set a “market outperform” rating on the stock in a research note on Thursday. Weiss Ratings downgraded Mirum Pharmaceuticals from a “sell (d)” rating to a “sell (d-)” rating in a report on Tuesday, June 23rd. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Mirum Pharmaceuticals from $115.00 to $125.00 and gave the stock an “overweight” rating in a research report on Thursday, July 2nd. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $137.33.

Institutional Investors Weigh In On Mirum Pharmaceuticals

A number of institutional investors have recently made changes to their positions in MIRM. Insight Wealth Partners LLC acquired a new position in shares of Mirum Pharmaceuticals in the second quarter valued at about $395,000. Bank of New York Mellon Corp bought a new position in shares of Mirum Pharmaceuticals during the second quarter worth approximately $78,434,000. State of Wyoming bought a new position in shares of Mirum Pharmaceuticals during the second quarter worth approximately $52,000. Handelsbanken Fonder AB raised its position in shares of Mirum Pharmaceuticals by 1.6% in the second quarter. Handelsbanken Fonder AB now owns 197,179 shares of the company’s stock valued at $23,084,000 after buying an additional 3,179 shares in the last quarter. Finally, Contravisory Investment Management Inc. raised its position in shares of Mirum Pharmaceuticals by 2.3% in the second quarter. Contravisory Investment Management Inc. now owns 4,604 shares of the company’s stock valued at $539,000 after buying an additional 103 shares in the last quarter.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.